- In April 2023, Thermo Fisher Scientific Inc., a global leader in scientific instrumentation, announced the launch of an advanced RNA visualization platform designed specifically for high-resolution microscopy-based imaging applications. The new platform integrates proprietary RNA labeling probes with super-resolution imaging technology, offering researchers unprecedented accuracy in tracking RNA molecules in live cells. This development underscores Thermo Fisher’s commitment to providing cutting-edge tools for molecular biology and transcriptomics research
- In March 2023, Bio-Techne Corporation expanded its portfolio of RNA detection reagents with the introduction of its novel RNAscope HiPlex assay, tailored for use in microscopy-based RNA imaging. The HiPlex assay allows for simultaneous detection of up to 12 RNA targets within the same tissue sample at single-cell resolution, significantly enhancing multiplexing capabilities. This innovation reflects Bio-Techne’s focus on empowering spatial biology and precision medicine initiatives
- In March 2023, Bruker Corporation unveiled its latest upgrade to the JPK NanoWizard BioAFM series, now optimized for integration with RNA imaging workflows in living cells. This integration provides enhanced spatial resolution and sensitivity, crucial for studying RNA-protein interactions at the nanoscale. The enhancement demonstrates Bruker’s strategy to support high-end life sciences applications through continual technological evolution
- In February 2023, Vizgen, a pioneer in spatial genomics, introduced its MERSCOPE Platform for the Asian market. The platform leverages MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology to enable single-molecule RNA detection and quantification in tissue samples, allowing for complex transcriptomic analysis with spatial context. This international expansion reflects Vizgen’s ambition to meet rising global demand for microscopy-based RNA imaging tools
- In January 2023, Advanced Cell Diagnostics (a Bio-Techne brand) announced the commercial availability of its RNAscope 4.0 technology, designed to streamline the imaging of RNA in fixed tissues using fluorescence microscopy. With enhanced signal amplification and reduced background noise, this next-generation solution provides researchers with clearer, more reliable visualization of gene expression patterns. The release further cements ACD’s position as a frontrunner in spatial transcriptomics and RNA-based diagnostics
